<DOC>
	<DOCNO>NCT01942083</DOCNO>
	<brief_summary>This Phase I , open label , non randomize , multicenter study design investigate safety tolerability escalate dos OPB-111077 administer orally , daily subject advance HCC .</brief_summary>
	<brief_title>A Phase I , Open Label , Non Randomized , Multicenter , Dose Escalation Clinical Study Investigate Safety Tolerability OPB ( Otsuka Pharmaceutical Biwa ) -111077 Subjects With Advanced HCC ( Hepatocellular Carcinoma )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Histopathologically clinically diagnose HCC Korean Liver Cancer Study Group ( KLCSG ) guideline . 2 . Subject advance HCC 3 . Documented evidence unresponsiveness , intolerance , ineligibility sorafenib , unavailability appropriate sorafenib treatment 4 . Male female subject , age consent ≥20 year ≤75 year . 5 . Life expectancy ≥12 week . 6 . Subjects agree partner ( ) practice contraception study period 3 month ( 12 week ) completion study treatment . 7 . Subjects informed diagnosis advance HCC fully inform content study Investigator use write consent form , give write consent participate study free . 1 . Past liver transplantation 2 . Uncontrollable hepatic encephalopathy ascites 3 . Presence brain metastases 4 . Clinically significant gastrointestinal bleeding past 6 month current active gastrointestinal bleeding . 5 . Primary malignancy HCC 6 . Human immunodeficiency virus ( HIV ) infection 7 . Severe poorly control complication may affect conduct result study . 8 . Use Interferon preparation within 4 week ( 28 day ) start study treatment present study . 9 . Pregnant , nursing , possibly pregnant woman , woman desire become pregnant study period 10 . Other case judge Investigator ineligible participation study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>